Vol. 5 No. 10 (2025)
Reimbursement Reviews

Rozanolixizumab (Rystiggo)

decorative image of the issue cover

Published October 7, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses rozanolixizumab (Rystiggo), 140 mg/mL, solution for injection (280 mg in 2 mL in single-dose glass vials) for SC use.
  • Indication: For the treatment of adult patients with gMG who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase inhibitor antibody positive.